Skip to main content
. Author manuscript; available in PMC: 2013 Sep 16.
Published in final edited form as: FEBS Lett. 2009 Mar 29;583(8):1386–1390. doi: 10.1016/j.febslet.2009.03.056

Table 1.

Oligonucleotides used in the study.

Namea Sequence (5' to 3')b Locationc
3'-end RNA ligation linker rAppTTTAACCGCGAATTCCAG/ddC
5'-end RNA ligation linker TGGAATrUrCrUrCrGrGrGrCrArCrCrArArGrGrU
miRNA-RT GCTGGAATTCGCGGTTAA
miRNA-Forward TGGAATTCTCGGGCACCA
F CGGCTTGAGGCCAAGAAC 61E U3LTR −197 to −180
R TCGAACTCTGGTCAACTG 61E U3LTR −94 to −111
M6 ACTGGGGAGCtcGGAGACTGC 61E U3LTR −108 to −128
M7 ATAGCAGAAttCGCGCGTACA 61E U3LTR −28 to −48
FeLV EnvA GTCAGGACAATAACTGTGAGG 61E gp70 6167 to 6187
FeLV EnvB CGGTCCCAATCCGTTTGGGAC 61E gp70 6499 to 6479
T7-F TAATACGACTCACTATAGGCGGCTTGA--GGCCAAGAAC T7 promoter at the 5' of `F'
a

Ligation linkers were purchased from Integrated DNA Technologies.

b

bases with a prefix `r' denote ribonucleotides, dd is dideoxynucleotide, lower case letters in M6 and M7 denote deviation from original sequence introduced to create restriction enzyme sites. T-7 promoter binding site is underlined in oligonucleotide primer T7-F.

c

Locations of the oligonucleotide primers are based on FeLV-A 61E sequence (Genbank accession number M18247) where +1 is the beginning of the genomic RNA transcript at R.